LAS VEGAS--(BUSINESS WIRE)--CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) today announced the completion of its pre-clinical research program to assess the effects of its protein-based drug candidate, CVBT-141F, in reducing brain damage due to stroke. Results from three independent animal studies, summarized in the accompanying graphic, demonstrated that CVBT 141F significantly reduced the stroke-affected area in the brain as compared to control groups, while treated animals had significantly less neurological defects as assessed by several behavioral tests.
